Cargando…
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer
The presence of tumor infiltrating lymphocytes (TILs) is associated with a longer overall survival in advanced stage epithelial ovarian cancer. Despite the prognostic impact of TILs, response to checkpoint-inhibitors and antigen-specific active immunotherapy is limited in ovarian cancer. The goal of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558014/ https://www.ncbi.nlm.nih.gov/pubmed/31214202 http://dx.doi.org/10.3389/fimmu.2019.01273 |
_version_ | 1783425537085014016 |
---|---|
author | Baert, Thaïs Vankerckhoven, Ann Riva, Matteo Van Hoylandt, Anaïs Thirion, Gitte Holger, Gerhardt Mathivet, Thomas Vergote, Ignace Coosemans, An |
author_facet | Baert, Thaïs Vankerckhoven, Ann Riva, Matteo Van Hoylandt, Anaïs Thirion, Gitte Holger, Gerhardt Mathivet, Thomas Vergote, Ignace Coosemans, An |
author_sort | Baert, Thaïs |
collection | PubMed |
description | The presence of tumor infiltrating lymphocytes (TILs) is associated with a longer overall survival in advanced stage epithelial ovarian cancer. Despite the prognostic impact of TILs, response to checkpoint-inhibitors and antigen-specific active immunotherapy is limited in ovarian cancer. The goal of our study was to investigate the interaction between ovarian cancer and the innate and adaptive immune system in the ID8-fLuc syngeneic ovarian cancer mouse model. For the in vivo experiments C57BL/6, B6.129S7-Rag1(tm1Mom)/J, and B6.129P2(SJL)-Myd88(tm1.1Defr)/J mice were inoculated with ID8-fLuc. In vivo depletion experiments were performed using clodronate liposomes (CL), anti-CD8a, anti-GR1, anti-colony stimulating factor 1 (anti-CSF1), and TMβ1 (anti-CD122). Immune read out was performed by fluorescent activated cell sorting analysis for effector T cells, regulatory T cells, natural killer cells, B cells, macrophages, and myeloid derived suppressor cells (MDSC), immunohistochemistry for MDSC and tumor-associated macrophages (TAM) and immunofluorescence for M1 and M2 TAM in the vascular context. The effect of MDSC on T cell proliferation and phenotype were studied in vitro. We discovered that the absence of T and B cells did not influence tumor growth or survival of B6.129S7-Rag1(tm1Mom)/J mice compared to immunocompetent C57BL/6 mice. CL-induced macrophage depletion promoted tumor proliferation and shortened survival in C57BL/6 mice (p = 0.004) and in B6.129S7-Rag1(tm1Mom)/J mice (p = 0.0005). During CL treatment, we observed a clear increase of pro-inflammatory cytokines (p ≤ 0.02) and monocytic MDSC (p ≤ 0.01). Selective depletion of MDSC by anti-GR1 improved survival, certainly in comparison to mice treated with anti-CSF1 (p = 0.01—median survival 91 vs. 67.5 days). B6.129P2(SJL)-Myd88(tm1.1Defr)/J mice displayed to a longer median survival compared to C57BL/6 mice (90 vs. 76 days). MDSC activated by ID8-fLuc conditioned medium or ascites of tumor-bearing mice showed T cell suppressive functions in vitro. Based on these findings, we conclude that the adaptive immune system does not efficiently control tumor growth in the ID8-fLuc model. In addition, we discovered a prominent role for MDSC as the driver of immunosuppression in the ID8-fLuc ovarian cancer mouse model. |
format | Online Article Text |
id | pubmed-6558014 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65580142019-06-18 Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer Baert, Thaïs Vankerckhoven, Ann Riva, Matteo Van Hoylandt, Anaïs Thirion, Gitte Holger, Gerhardt Mathivet, Thomas Vergote, Ignace Coosemans, An Front Immunol Immunology The presence of tumor infiltrating lymphocytes (TILs) is associated with a longer overall survival in advanced stage epithelial ovarian cancer. Despite the prognostic impact of TILs, response to checkpoint-inhibitors and antigen-specific active immunotherapy is limited in ovarian cancer. The goal of our study was to investigate the interaction between ovarian cancer and the innate and adaptive immune system in the ID8-fLuc syngeneic ovarian cancer mouse model. For the in vivo experiments C57BL/6, B6.129S7-Rag1(tm1Mom)/J, and B6.129P2(SJL)-Myd88(tm1.1Defr)/J mice were inoculated with ID8-fLuc. In vivo depletion experiments were performed using clodronate liposomes (CL), anti-CD8a, anti-GR1, anti-colony stimulating factor 1 (anti-CSF1), and TMβ1 (anti-CD122). Immune read out was performed by fluorescent activated cell sorting analysis for effector T cells, regulatory T cells, natural killer cells, B cells, macrophages, and myeloid derived suppressor cells (MDSC), immunohistochemistry for MDSC and tumor-associated macrophages (TAM) and immunofluorescence for M1 and M2 TAM in the vascular context. The effect of MDSC on T cell proliferation and phenotype were studied in vitro. We discovered that the absence of T and B cells did not influence tumor growth or survival of B6.129S7-Rag1(tm1Mom)/J mice compared to immunocompetent C57BL/6 mice. CL-induced macrophage depletion promoted tumor proliferation and shortened survival in C57BL/6 mice (p = 0.004) and in B6.129S7-Rag1(tm1Mom)/J mice (p = 0.0005). During CL treatment, we observed a clear increase of pro-inflammatory cytokines (p ≤ 0.02) and monocytic MDSC (p ≤ 0.01). Selective depletion of MDSC by anti-GR1 improved survival, certainly in comparison to mice treated with anti-CSF1 (p = 0.01—median survival 91 vs. 67.5 days). B6.129P2(SJL)-Myd88(tm1.1Defr)/J mice displayed to a longer median survival compared to C57BL/6 mice (90 vs. 76 days). MDSC activated by ID8-fLuc conditioned medium or ascites of tumor-bearing mice showed T cell suppressive functions in vitro. Based on these findings, we conclude that the adaptive immune system does not efficiently control tumor growth in the ID8-fLuc model. In addition, we discovered a prominent role for MDSC as the driver of immunosuppression in the ID8-fLuc ovarian cancer mouse model. Frontiers Media S.A. 2019-06-04 /pmc/articles/PMC6558014/ /pubmed/31214202 http://dx.doi.org/10.3389/fimmu.2019.01273 Text en Copyright © 2019 Baert, Vankerckhoven, Riva, Van Hoylandt, Thirion, Holger, Mathivet, Vergote and Coosemans. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Baert, Thaïs Vankerckhoven, Ann Riva, Matteo Van Hoylandt, Anaïs Thirion, Gitte Holger, Gerhardt Mathivet, Thomas Vergote, Ignace Coosemans, An Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
title | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
title_full | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
title_fullStr | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
title_full_unstemmed | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
title_short | Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer |
title_sort | myeloid derived suppressor cells: key drivers of immunosuppression in ovarian cancer |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558014/ https://www.ncbi.nlm.nih.gov/pubmed/31214202 http://dx.doi.org/10.3389/fimmu.2019.01273 |
work_keys_str_mv | AT baertthais myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT vankerckhovenann myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT rivamatteo myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT vanhoylandtanais myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT thiriongitte myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT holgergerhardt myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT mathivetthomas myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT vergoteignace myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer AT coosemansan myeloidderivedsuppressorcellskeydriversofimmunosuppressioninovariancancer |